FINWIRES · TerminalLIVE
FINWIRES

Amplitude Energy Represents Compelling Buying Opportunity at Current Share Price, Euroz Hartleys Says

By

Amplitude Energy (ASX:AEL) is expected to deliver record performance in the fiscal fourth quarter and represents a compelling buying opportunity at its current share price, Euroz Hartleys said in a Monday note.

The equity research firm said it expects the company to perform well in fiscal Q4 due to continued production de-bottlenecking at its Orbost gas asset in Victoria, incremental production from other basins, including new Callawonga oil wells in the Cooper Basin, as well as an expected rise in spot gas prices.

Euroz Hartleys forecasts fiscal Q4 production of 7 petajoules equivalent and revenue of AU$86.7 million for Amplitude. It also lowered its forecast for the company's fiscal year capital expenditure to AU$136 million, resulting in a lower estimated year-end net debt position.

Additionally, Euroz Hartleys said it maintains high confidence in the phase two outcomes of the company's East Coast Supply Project, given its "location in the core producing area of the Otway Basin and compelling geophysical signatures/simple trapping geometries of the targets."

The equity research firm maintained a buy recommendation on the company and raised its price target to AU$3.40 per share from AU$3.25, reflecting an updated risked sum-of-the-parts valuation.

Shares of Amplitude Energy were down 1% in recent Monday trade.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA